$3.71
0.27%
NYSE, Aug 29, 10:00 pm CET
ISIN
US5019761049
Symbol
KYTX

Kyverna Therapeutics Stock price

$3.71
-0.14 3.64% 1M
+0.87 30.63% 6M
-0.03 0.80% YTD
-4.31 53.74% 1Y
-18.29 83.14% 3Y
-18.29 83.14% 5Y
-18.29 83.14% 10Y
-18.29 83.14% 20Y
NYSE, Closing price Fri, Aug 29 2025
+0.01 0.27%
ISIN
US5019761049
Symbol
KYTX
Industry

Key metrics

Basic
Market capitalization
$160.4m
Enterprise Value
$-50.9m
Net debt
positive
Cash
$211.7m
Shares outstanding
43.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.4
P/B
0.9
Financial Health
Equity Ratio
87.5%
Return on Equity
-47.6%
ROCE
-91.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-169.5m | $-191.6m
EBIT
$-171.6m | $-185.7m
Net Income
$-158.7m | $-168.0m
Free Cash Flow
$-142.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-39.3% | -36.0%
EBIT
-38.0% | -29.9%
Net Income
-36.4% | -32.3%
Free Cash Flow
-35.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.7
FCF per Share
$-3.3
Short interest
6.4%
Employees
129
Rev per Employee
$0.0
Show more

Is Kyverna Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Kyverna Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Kyverna Therapeutics forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Kyverna Therapeutics forecast:

Buy
92%
Hold
8%

Financial data from Kyverna Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 36 36
40% 40%
-
- Research and Development Expense 136 136
36% 36%
-
-169 -169
39% 39%
-
- Depreciation and Amortization 2.14 2.14
21% 21%
-
EBIT (Operating Income) EBIT -172 -172
38% 38%
-
Net Profit -159 -159
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kyverna Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kyverna Therapeutics Stock News

Neutral
GlobeNewsWire
4 days ago
KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome
Neutral
GlobeNewsWire
7 days ago
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the following upcoming conferences:
Neutral
GlobeNewsWire
20 days ago
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026
More Kyverna Therapeutics News

Company Profile

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Head office United States
CEO Warner Biddle
Employees 129
Founded 2018
Website kyvernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today